Lucia Carpineta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lucia Carpineta has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Pedro A.B. Albuquerque
Department of Medical Imaging, Montreal Children’s Hospital, McGill University, Montreal, Quebec, Canada
3 shared publicationsD. Alicia Morales Ramos
2 shared publications- Lily H. P. Nguyen
McGill University
2 shared publications Mark Anselmo
Division of Respiratory Medicine, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montréal, Québec, Canada
2 shared publications- Martin Bitzan
McGill University
2 shared publications - Ricardo Faingold
Department of Diagnostic Imaging, The Montreal Children's Hospital, Montreal, Quebec, Canada
2 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 109, 158-163
Hearing loss in pediatric temporal bone fractures: Evaluating two radiographic classification systems as prognosticators
- 1 June 2018
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 109, 158-163
Hearing loss in pediatric temporal bone fractures: Evaluating two radiographic classification systems as prognosticators
- 1 May 2016
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 84, 106-109
Pediatric temporal bone fractures: A case series
- 1 May 2016
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 84, 106-109
Pediatric temporal bone fractures: A case series
- 1 December 2013
- Published by Elsevier in Clinical Radiology
- Vol. 68 (12) , 1212-1219
Appendicitis in adults with incidental midgut malrotation: CT findings
- 1 December 2013
- Published by Elsevier in Clinical Radiology
- Vol. 68 (12) , 1212-1219
Appendicitis in adults with incidental midgut malrotation: CT findings
- 31 March 2012
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology Extra
- Vol. 7 (2) , 70-72
Cystic fibrosis presenting as bilateral maxillary mucoceles in an infant
- 31 March 2012
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology Extra
- Vol. 7 (2) , 70-72
Cystic fibrosis presenting as bilateral maxillary mucoceles in an infant
- 31 July 2011
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 49 (4) , 679-687
Hepatobiliary Tumors
- 31 July 2011
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 49 (4) , 679-687
Hepatobiliary Tumors
- 15 March 2010
- Published by Wiley in Pediatric Pulmonology
- Vol. 45 (4) , 414-416
Reply: Rituximab-induced pneumonitis: Steroid therapy or not?
- 15 March 2010
- Published by Wiley in Pediatric Pulmonology
- Vol. 45 (4) , 414-416
Reply: Rituximab-induced pneumonitis: Steroid therapy or not?
- 6 February 2010
- Published by Springer Nature in Pediatric Nephrology
- Vol. 25 (6) , 1163-1167
Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease
Cryptogenic organizing pneumonia (COP, formerly bronchiolitis obliterans organizing pneumonia) is rare in children. We describe an 11-year-old girl with Epstein–Barr virus (EBV) reactivation/presumed post-transplant lymphoproliferative disease (PTLD) 15 months after undergoing a deceased donor kidney transplantation. Treatment with reduced immunosuppression, ganciclovir, and cytomegalovirus immunoglobulin was complicated by severe graft rejection, prompting therapy with methylprednisolone, anti-thymocyte globulin and four weekly doses of rituximab (total 1500 mg/m2). Tacrolimus- and prednisone-based anti-rejection prophylaxis was complemented with low-dose sirolimus. When the lactate dehydrogenase and uric acid levels rose 10 weeks after the first rituximab infusion and bilateral pulmonary nodules were detected by computerized tomography, recurrence of PTLD was suspected. Open lung biopsy of the clinically asymptomatic patient identified the nodules as COP, characterized by abundant CD3+ T-cells, few B-cells, and the absence of EBV, cytomegalovirus, or adenovirus antigens. With normalization of the peripheral B-cell count, EB viremia reappeared and persisted, despite minimal immunosuppression. Four years later, the patient was diagnosed with classical Hodgkin lymphoma-type PTLD with multiple pulmonary and abdominal nodes. This first report of rituximab-associated, pediatric COP highlights the risk of pulmonary complications after treatment with B-cell depleting agents in solid organ transplant recipients, and the importance of a histopathologic diagnosis and vigilant follow-up of such lesions.
- 6 February 2010
- Published by Springer Nature in Pediatric Nephrology
- Vol. 25 (6) , 1163-1167
Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease
Cryptogenic organizing pneumonia (COP, formerly bronchiolitis obliterans organizing pneumonia) is rare in children. We describe an 11-year-old girl with Epstein–Barr virus (EBV) reactivation/presumed post-transplant lymphoproliferative disease (PTLD) 15 months after undergoing a deceased donor kidney transplantation. Treatment with reduced immunosuppression, ganciclovir, and cytomegalovirus immunoglobulin was complicated by severe graft rejection, prompting therapy with methylprednisolone, anti-thymocyte globulin and four weekly doses of rituximab (total 1500 mg/m2). Tacrolimus- and prednisone-based anti-rejection prophylaxis was complemented with low-dose sirolimus. When the lactate dehydrogenase and uric acid levels rose 10 weeks after the first rituximab infusion and bilateral pulmonary nodules were detected by computerized tomography, recurrence of PTLD was suspected. Open lung biopsy of the clinically asymptomatic patient identified the nodules as COP, characterized by abundant CD3+ T-cells, few B-cells, and the absence of EBV, cytomegalovirus, or adenovirus antigens. With normalization of the peripheral B-cell count, EB viremia reappeared and persisted, despite minimal immunosuppression. Four years later, the patient was diagnosed with classical Hodgkin lymphoma-type PTLD with multiple pulmonary and abdominal nodes. This first report of rituximab-associated, pediatric COP highlights the risk of pulmonary complications after treatment with B-cell depleting agents in solid organ transplant recipients, and the importance of a histopathologic diagnosis and vigilant follow-up of such lesions.
- 13 August 2009
- Published by Wiley in Pediatric Pulmonology
- Vol. 44 (9) , 922-934
Rituximab (B‐cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature
Introduction: Pulmonary toxicity of delayed onset is a rare complication of B‐lymphocyte depleting antibody therapy and has been almost exclusively reported in older patients with B‐cell malignancies.Aims: To describe a pediatric patient with rituximab‐associated lung injury (RALI), to systematically analyze previous reports of pulmonary complications, and to summarize common clinico‐pathological features, treatment, and outcome.Results: A teenage boy with focal segmental glomerulosclerosis (FSGS) presented with progressive dyspnea, fever, hypoxemia and fatigue 18 days after the completion of a second course of rituximab infusions for calcineurin inhibitor‐dependent nephrotic syndrome. Respiratory symptoms started while he received high‐dose prednisone for persistent proteinuria. Bilateral, diffuse ground‐glass infiltrates corresponded to the presence of inflammatory cells in the bronchioalveolar lavage fluid. Empiric antibiotic treatment including clarithromycin was given, but the microbiological work‐up remained negative. Serum IgE, C3, and C4 concentrations were normal. He recovered within 3 weeks after onset.We systematically reviewed 23 reports describing 30 additional cases of rituximab‐associated lung disease. Twenty eight patients had received rituximab for B‐cell malignancies, one for graft‐versus‐host disease and one for immune thrombocytopenia. Median age was 64 years (interquartile range [IQR] 58–69 years). Seventy one percent received concomitant chemotherapy. Time to onset from the last rituximab dose was 14 days (IQR 11–22 days). Eleven of 31 patients required mechanical ventilation, and 9 died (29%). Ventilation was a significant predictor of fatal outcome (odds ratio 46.7; confidence interval 9.5–229.9). High dose glucocorticoid therapy did not improve survival or prevent severe lung disease or death.Conclusions: With the expanding use of rituximab for novel indications, additional cases of RALI affecting younger age groups are expected to emerge. Mechanical ventilation predicts poor outcome. Glucocorticoids may not be protective. Pediatr Pulmonol. 2009; 44:922–934.
- 13 August 2009
- Published by Wiley in Pediatric Pulmonology
- Vol. 44 (9) , 922-934
Rituximab (B‐cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature
Introduction: Pulmonary toxicity of delayed onset is a rare complication of B‐lymphocyte depleting antibody therapy and has been almost exclusively reported in older patients with B‐cell malignancies.Aims: To describe a pediatric patient with rituximab‐associated lung injury (RALI), to systematically analyze previous reports of pulmonary complications, and to summarize common clinico‐pathological features, treatment, and outcome.Results: A teenage boy with focal segmental glomerulosclerosis (FSGS) presented with progressive dyspnea, fever, hypoxemia and fatigue 18 days after the completion of a second course of rituximab infusions for calcineurin inhibitor‐dependent nephrotic syndrome. Respiratory symptoms started while he received high‐dose prednisone for persistent proteinuria. Bilateral, diffuse ground‐glass infiltrates corresponded to the presence of inflammatory cells in the bronchioalveolar lavage fluid. Empiric antibiotic treatment including clarithromycin was given, but the microbiological work‐up remained negative. Serum IgE, C3, and C4 concentrations were normal. He recovered within 3 weeks after onset.We systematically reviewed 23 reports describing 30 additional cases of rituximab‐associated lung disease. Twenty eight patients had received rituximab for B‐cell malignancies, one for graft‐versus‐host disease and one for immune thrombocytopenia. Median age was 64 years (interquartile range [IQR] 58–69 years). Seventy one percent received concomitant chemotherapy. Time to onset from the last rituximab dose was 14 days (IQR 11–22 days). Eleven of 31 patients required mechanical ventilation, and 9 died (29%). Ventilation was a significant predictor of fatal outcome (odds ratio 46.7; confidence interval 9.5–229.9). High dose glucocorticoid therapy did not improve survival or prevent severe lung disease or death.Conclusions: With the expanding use of rituximab for novel indications, additional cases of RALI affecting younger age groups are expected to emerge. Mechanical ventilation predicts poor outcome. Glucocorticoids may not be protective. Pediatr Pulmonol. 2009; 44:922–934.
- 1 March 2009
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 33 (3) , 475-482
Polypoid PEComa in the Rectum of a 15-year-old Girl
PEComa of the gastrointestinal tract, composed of perivascular epithelioid cells with myomelanocytic differentiation, is rare with previous literature limited to 16 case reports. There is a marked female preponderance and approximately one-third of the cases occur in the pediatric age group. We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy. The patient is well at 9 months follow-up with neither radiologic nor endoscopic evidence of recurrence. We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma. Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction. We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome. All 4 tumors reporting early recurrence or progression were greater than 5 cm in size and had areas of coagulative tumor necrosis. In addition, high nuclear grade and lymphovascular invasion were seen in 2 of these 4 cases. We propose that a minimum dataset for gastrointestinal PEComa should include these features along with mitotic count, infiltrative border, and tumor stage analogous to that used in colorectal carcinoma.
- 1 March 2009
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 33 (3) , 475-482
Polypoid PEComa in the Rectum of a 15-year-old Girl
PEComa of the gastrointestinal tract, composed of perivascular epithelioid cells with myomelanocytic differentiation, is rare with previous literature limited to 16 case reports. There is a marked female preponderance and approximately one-third of the cases occur in the pediatric age group. We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy. The patient is well at 9 months follow-up with neither radiologic nor endoscopic evidence of recurrence. We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma. Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction. We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome. All 4 tumors reporting early recurrence or progression were greater than 5 cm in size and had areas of coagulative tumor necrosis. In addition, high nuclear grade and lymphovascular invasion were seen in 2 of these 4 cases. We propose that a minimum dataset for gastrointestinal PEComa should include these features along with mitotic count, infiltrative border, and tumor stage analogous to that used in colorectal carcinoma.
- 18 December 2008
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 25 (1) , 11-14
Spinal Hamartoma with Severe Kyphoscoliosis – A Rare Case of Spinal Mass in a Fetus
Spinal hamartomas are rare lesions consisting of disorganized ecto- and mesodermal tissues of the spinal region. While postnatal identification of spinal hamartomas has been reported, a literature search did not reveal any published reports of prenatal identification of spinal hamartomas. Here we report a 46,XX fetus who presented at 20 weeks’ gestation with a lower thoracic and lumbar kyphoscoliosis, suspected spina bifida, and amniotic fluid α-fetoprotein (AFP) levels within the normal range. Interestingly, autopsy at 22 weeks revealed a lumbosacral spinal hamartoma with kyphoscoliosis. We discuss the differential diagnosis for such spinal masses which includes congenital tumors and spinal dysraphism. This case illustrates that spinal hamartomas should be considered as part of the prenatal differential diagnosis of spinal dysraphisms, especially in the presence of normal AFP levels.
- 18 December 2008
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 25 (1) , 11-14
Spinal Hamartoma with Severe Kyphoscoliosis – A Rare Case of Spinal Mass in a Fetus
Spinal hamartomas are rare lesions consisting of disorganized ecto- and mesodermal tissues of the spinal region. While postnatal identification of spinal hamartomas has been reported, a literature search did not reveal any published reports of prenatal identification of spinal hamartomas. Here we report a 46,XX fetus who presented at 20 weeks’ gestation with a lower thoracic and lumbar kyphoscoliosis, suspected spina bifida, and amniotic fluid α-fetoprotein (AFP) levels within the normal range. Interestingly, autopsy at 22 weeks revealed a lumbosacral spinal hamartoma with kyphoscoliosis. We discuss the differential diagnosis for such spinal masses which includes congenital tumors and spinal dysraphism. This case illustrates that spinal hamartomas should be considered as part of the prenatal differential diagnosis of spinal dysraphisms, especially in the presence of normal AFP levels.